Bio-Technopark
In very close proximity to the Swiss Federal Institute of Technology (ETH), the University and Zurich University Hospital, a science park for life science companies and institutions has developed in the last two decades, which has now acquired both national and international significance. On the former site of the Schweizerische Wagons- und Aufzügefabrik AG and on neighboring sites, 100,000 m2 of laboratory, production and office space is now leased to around 60 companies and organizations, and 80 academic research groups. Video
Leasing
In the Bio-Technopark, it is possible to rent ultramodern laboratories, offices, and complex infrastructure for research and development purposes. The premises offered include fully-equipped laboratory facilities with partly shared infrastructure, and individual rental areas in different sizes and locations and with different fit-out standards. The Bio-Technopark is still being developed and gradually fitted out.
Services
The Bio-Technopark promotes the transfer of knowledge and technology, as well as the foundation and building up of life science companies. In addition to advice, coaching, and support for those who are setting up and developing companies and looking for financing, its services include the organization of events that focus on networking, facilitating the exchange of ideas between specialists, and advanced training.
News
Kuros Biosciences increases 2026 annual guidance, The company reports 40% year-over-year increase in sales in the first nine months of 2026
Kuros Biosciences increases 2026 annual guidance The company reports 40% year-over-year increase in sales in the first nine months of 2026 Schlieren (Zurich), Switzerland, October 15, 2026 – Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation bone healing technologies, today announced its financial performance for the first nine months...
AL-S Pharma Appoints Harry Welten as Chief Executive Officer
ZURICH, Switzerland – October 14, 2026 – AL-S Pharma AG (“AL-S Pharma” or “the Company”), a clinical-stage biotechnology company discovering and developing human antibodies that target misfolded proteins implicated in amyotrophic lateral sclerosis (ALS), today announced the appointment of Harry Welten as chief executive officer (CEO). Mr. Welten succeeds Michael...